(Ocaratuzumab)Biosimilar Reference Antibody-GS40486 新品

货号：GS40486

Ocaratuzumab (also known as AME‑133v or LY2469298) is a humanized, Fc‑engineered monoclonal antibody that targets CD20, a B‑cell surface antigen. Its Fc region is engineered (with enhanced affinity for FcγRIIIa) to potentiate antibody‑dependent cellular cytotoxicity (ADCC) against CD20‑positive B cells. Compared to the first‑generation anti‑CD20 antibody rituximab, ocaratuzumab is designed to provide stronger ADCC, particularly in patients carrying the lower‑affinity FcγRIIIa‑158F polymorphism. It was developed as a potential therapy for B‑cell non‑Hodgkin lymphoma (NHL) and was evaluated in clinical trials for relapsed/refractory follicular lymphoma, but its development has been discontinued.